Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Galvanize Therapeutics | 2025 | Series C | $100.0M | San Carlos |
| Bambusa Therapeutics | 2025 | Series A | $90.0M | Boston |
| Attralus | 2024 | Series B | $56.0M | San Francisco |
| Parse Biosciences | 2023 | Series C | $50.0M | Seattle |
| TwinStrand Biosciences | 2023 | Venture - Series Unknown | $10.3M | Seattle |
| Diagonal Therapeutics | 2026 | Series B | $125.0M | Watertown |
| Phathom Pharmaceuticals | 2026 | Post-IPO Equity | $130.0M | Florham Park |
| Synthekine | 2023 | Series C | $100.0M | Menlo Park |
| Vaxcyte | 2026 | Post-IPO Equity | $632.5M | San Carlos |
| Structure Therapeutics | 2025 | Post-IPO Equity | $747.5M | South San Francisco |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Galvanize Therapeutics | Series C | $100.0M | San Carlos, United States |
| 77 | Bambusa Therapeutics | Series A | $90.0M | Boston, United States |
| 78 | Attralus | Series B | $56.0M | San Francisco, United States |
| 79 | Parse Biosciences | Series C | $50.0M | Seattle, United States |
| 80 | TwinStrand Biosciences | Venture - Series Unknown | $10.3M | Seattle, United States |
| 81 | Diagonal Therapeutics | Series B | $125.0M | Watertown, United States |
| 82 | Phathom Pharmaceuticals | Post-IPO Equity | $130.0M | Florham Park, United States |
| 83 | Synthekine | Series C | $100.0M | Menlo Park, United States |
| 84 | Vaxcyte | Post-IPO Equity | $632.5M | San Carlos, United States |
| 85 | Structure Therapeutics | Post-IPO Equity | $747.5M | South San Francisco, United States |
Galvanize is a biomedical platform company that provides therapeutic products and services to deliver healthcare solutions.
Bambusa Therapeutics operates as biotechnology company.
Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.
Parse Biosciences is a biotechnology startup company that develops single-cell sequencing kit solutions for researchers.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.
Phathom Pharmaceuticals is a biopharmaceutical company.
Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.
Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.
Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.
Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Janux Therapeutics develops immunotherapies that generates immune responses to prevent tumors and not affecting a patient’s healthy tissue.
Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.
Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.
CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Ambros Therapeutics is a clinical-stage biotechnology company.
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
nChroma Bio is a cutting-edge biotechnology business that is developing targeted in vivo delivery systems as well as best-in-class cargo.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.
Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
Janus Henderson Investors has invested in 213 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Janus Henderson Investors's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Pharmaceutical. The firm invests across 14 different industry categories.
Among tracked funding rounds, Structure Therapeutics received $747.5M in a Post-IPO Equity round. Janus Henderson Investors's total known invested capital is $26.3B.
Janus Henderson Investors's average investment size is $142.2M across its portfolio of 213 companies.
Recent Janus Henderson Investors portfolio additions include Galvanize Therapeutics, Bambusa Therapeutics, Attralus, Parse Biosciences, TwinStrand Biosciences. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors